Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

ANKI- Lung > Lung > Flashcards

Lung Flashcards

1
Q

front

A

back

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How did the WashU RT lung toxicity differ from the STRIPE trial?

A

42% of patients in the WashU study received concurrent CRT while 100% of patients in the STRIPE trial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What was the study population in the Peking study investigating cis/etop vs carbo/taxol?

A

Unresectable stage III NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What was 3-and 5-year primary control and distant metastasis rate in the RTOG 0236 trial?

A

3-yr primary control: 98%<div>5-yr primary control: 93%</div><div><br></br></div><div>3-yr DM 22%</div><div>5-yr DM 24%</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

<div>In the NRG/RTOG0915 trial, what was grade 3 toxicity and 5-yr primary control in the 34Gy/1fx vs 48/4fx?</div>

A

34 vs 48 Gy:<div>2.6% vs 11% grade 3 toxicity</div><div>89% vs 93% primary control</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which group demonstrated low regional failure with omission of ENI in SCLC? (i.e. RT only directed to FDG avid areas)

A

Maastricht University, The Netherlands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What did the CASPIAN trial in extensive stage SCLC study?

A

durvalumab + tremelimumab + plat/etop<div>vs</div><div>durvalumab + plat/etop</div><div>vs</div><div>plat/etop</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What was predictive of radiation pneumonitis in the STRIPE trial?

A

-carbo/paclitaxel<div>-V20 (total lung - GTV)</div><div>->2Gy/fx</div><div>-lower lobe</div><div>-Age >65</div><div><br></br></div><div>If both age >65 and treated with carbo/taxol, then >50% risk of symptomatic pneumonitis</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What did the ‘CHISEL’ study investigate and what was it’s study population?

A

The CHISEL study compared SBRT vs EBRT in patients with T1-2 N0 M0 inoperable or refusing surgery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What was the pCR in patients of the MISSILE trial treated with SBRT?

A

pCR 60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What did the Netherlands Cancer Institute study in metastatic NSCLC?

A

Phase II trial, compared<div>SBRT 24 Gy in 3 fx followed by pembrolizumab</div><div>to</div><div>pembroluzimab</div><div><br></br></div><div>Prespecified endpoint was 3-month overall response rate of 50% vs 20%</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the IMpower133 trial in extensive stage SCLC?

A

atezolizumab (anti PD-L1) + carbo/etop<div>vs</div><div>placebo + carbo/etop</div><div><br></br></div><div>PCI allowed but not chest RT</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which study population did the LUNG-ART trial study and what was the trial set-up?

A

pN2 NSCLC, s/p complete resenction<div><br></br></div><div>Goal of the study was to investigate adjuvant RT in N2 disease</div><div>patients received</div><div>post-op 54 Gy in 27-30 fx</div><div>vs</div><div>No RT</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What was the focus of the SWOG 9416 / INT 0160 study?

A

Superior sulcus tumors!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What was the difference between the SABR-COMET trial, the SINDAS trial, the OliGomez MDACC trial and the IAEA trial?

A

SABR-COMET trial: RT in oligometastastic disease of ANY histology<div>SINDAS trial: RT in oligometastatic NSCLC EGFR+</div><div>OliGomez MDACC: <u>Local consolidative therapy</u> in oligometastatatic NSCLC after chemo</div><div>IAEA: RT in oligometastatic NSCLC</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe general study results of the CONVERT trial

A

Outcomes (OS and PFS) trended in favor of BID RT<div>The trial was designed to show superiority and did not –> BID fractionation remains standard</div><div><br></br></div><div>Median OS was 30 months for the BID group (slightly larger than in the Turrisi/INT0096 trial)</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which patients did the CREST study investigate?

A

ES-SCLC who responded to chemo, ECOG 0-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What were study methods of the CREST study in ES-SCLC who responded to chemo?

A

30 Gy thoracic RT + PCI<div>vs</div><div>PCI</div><div><br></br></div><div>Primary endpoint was 1-yr os</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What was the regimen studied in the INT 0139/RTOG 9309?

A

Neoadjuvant CRT + Surgery vs Definitive RT<div>In particular:</div><div>45 Gy with concurrent cis/etoposide</div><div>if no PD</div><div>–> Surgery vs RT to 61 Gy total</div><div>Then adjuvant x2 cis/etoposide in both arms</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What was median OS in CALGB 39801 for induction vs no induction chemo?

A

12 months vs 14 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What did the CALGB 39904 trial investigate?

A

Hypofractionation (70 Gy in various doses) in stage I NSCLC (<= 4cm) and poor pulmonary function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What was 2-year DFS and 2-year CNS FFR in the ADAURA trial comparing adjuvant osimertinib for 3 years vs placebo in EGFR+ NSCLC? What was the conclusion based on these findings?

A

Overall 2-year DFS was 89% vs 52%<div>2-year CNS FFR was 98% vs 85%</div><div><br></br></div><div>Conclusion: osimertinib improves DFS and reduces CNS relapse in completely resected EGFR+ NSCLC</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What were SBRT doses in SABR-COMET?

A

SBRT to 30-60Gy/3-8 fx<div>or single fx of 16-24 Gy for brain, spine</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What was median PFS in the SABR-COMET trial?

A

12 vs 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is the Goustave-Roussy study?

A

A meta-analysis of 6 trials evaluating concurrent vs sequential chemoRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What did CALGB 39801 investigate?

A

No induction chemo vs Induction chemo (2 cycles of carboplatin and paclitaxel) in patients with unresectable stage III NSCLC<div><br></br></div><div>Otherwise, all patients received 66 Gy Rt with concurrent weekly x7 weeks carboplatin and paclitaxel</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What was the conclusion of the CALGB 39801?

A

The addition of 2 cycles of induction carboplatin and paclitaxel increased toxicity and provided no OS benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Explain the radiation regimen for both arms in the CHISEL study.

A

SBRT 54 Gy / 3 fx (or 48 Gy / 4 fx if <2cm from chest wall)<div>vs</div><div>3D CRT to 66 Gy, or 50 GY in 20 fx</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What was the conclusion of the CHISEL study?

A

SBRT improved LC and OS compared to conventional RT.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Which SBRT dose did the NRG/RTOG 0915 investigate?

A

34 Gy / 1 fx<div>vs</div><div>45 Gy / 4 fx</div><div><br></br></div><div>Medically inoperable T1-T2N0M0 peripheral lesions</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is the conclusion of the caspian trial?

A

Durvalumab + platinum/etoposide improves OS in extensive stage SCLC compared to chemo alone.<div>The addition of tremelimumab to durvalumab + chemo did not improve outcomes</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

<div>What were the lung constraints in the TROVO trial?</div>

A

Contralateral lung V5 < 17%<div>Mean lung < 24 Gy</div><div><br></br></div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

In the SWOG trial, what was the 2-and 5-yr OS in all patients and in the patients with complete resection?

A

All patients: 2yr OS 55%, 5yr OS 44%<div>In patients with complete resection: 2yr OS 70%, 5yr OS 53%</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What was 2-yr LC, median OS and 2-yrs OS in the CHISEL study?

A

<div>For SBRT vs EBRT:</div>

2-yr LC was 89% vs 65%<div>Median OS was 5 yrs vs 3 yrs</div><div>2-yr OS was 77% vs 59%</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What was RT volume in the CREST trial investigating thoracic RT in ES-SCLC?

A

RT volume was post-chemo volume of involved nodal levels with 1.5 cm margin. Involved levels were included whether CR or not.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What did the SMART trial (Clive et al., Lancet Oncol) evaluate in mesothelioma patients?

A

Immediate vs deferred RT (for later mets) to tracts<div>RT to tract was 21 Gy / 3fx</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Which trials established improved OS with concurrent CRT vs sequential CRT?

A

RTOG 9410 and Goustave-Roussy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What was the regimen studied in the RTOG 0617?

A

Dose escalation, cetuximab being;<div>60 Gy vs 74 Gy</div><div>and</div><div>cetuximab (concurrent and consolidation) vs no cetuximab</div><div><br></br></div><div>All patients received carbo/taxol concurrent weekly and ajuvant x2!</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What did the STRIPE study investigate?

A

Meta-analysis of 12 studies investigating RT lung toxicity with chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What did the CALGB 8433 study?

A

RT alone vs induction + RT in locally advanced NSCLC<div>RT 60 Gy</div><div>induction: cis/vinblastine</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What were the results and the interpretation of the Lung Cancer Study group 821?

A

Improved LC with lobectomy over wedge<div>Trend to increase in overall death and cancer death with wedge resection</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What did the ANITA trial study?

A

The ANITA trial investigated adjuvant chemo vs observation in resected stage IB-IIIA patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What is another name for the LUNG-ART study?

A

EORTC 22055

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What was the rate of DM in squamous vs nonsquamous NSCLC in the RTOG 0236 which investigated SBRT in peripheral lesions.

A

DM in squamous 6%, nonsquamous 32%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What was the conclusion of a Pfizer study evaluating crizotinib in advanced NSCLC with ROS1 rearrangement?

A

Crizotinib has impressive response rates in ROS1 rearranged tumors<div><br></br></div><div>ORR:72%</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What did the Turrisi trial/INT0096 establish?

A

45 Gy/30 fx BID as standard therapy for limited-stage SCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

How was the hippocampal avoidance region created in the PREMER trial?

A

The hippocampus was contoured after which a 5-mm volumetric expansion was created around the hippocampus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Which country first established success with consolidative thoracic RT in ES-SCLC?<div>Describe their methods.</div>

A

Yugoslavia<div>they investigated</div><div><br></br></div><div>cis/etop x3 then if distant CR and local CR/PR</div><div>–> thoracic RT 54 Gy/36 fx BID + cis/etop x2</div><div>vs</div><div>cis/etop x4 followed by PCI</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What was the incidence of grade >= 2 pneumonitis and grade >=3 esophagitis in the Peking study (cis/etop vs carbo/taxol)?<div>Break-down per group.</div>

A

Grade >= 2 pneumonitis 19% vs 33%<div>Grade >= 3 esophagitis 20% vs 6%</div><div>for</div><div>cis/etop vs carbo/taxol</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Describe study set-up of the SCLC Turrisi trial aka as INT 0096.

A

Patients with limited stage SCLC were included<div>45 Gy in 1.8 Gy daily</div><div>vs</div><div>45 Gy in 1.5 Gy BID fractions</div><div><br></br></div><div>WITH concurrent cisplatin and etoposide x4 cycles q3 weeks</div><div>RT started with cycle 1</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What was the main criticism of the THORA trial comparing 45Gy BID vs 60Gy in 40 for limited stage SCLC?

A

Not analyzed according to ITT!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What were the results in terms of 2-yr OS in the PORT MetaAnalysis trialists group?

A

2-yr OS of 58% vs 53% with PORT<div>–> PORT worsens OS in early stage, resected NSCLC</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

In the EORTC 08941, how many of patient in the surgery arm received PORT?

A

40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What did the CONVERT trial study?

A

Dose escalation in limited-stage SCLC<div><br></br></div><div>cis/etop x1, then</div><div>45 Gy in 1.5 Gy BID or 66 Gy in 33 fx</div><div><br></br></div><div>4-6 cycles cis/etop</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

What was the conclusion of the Japanese PCI trial? (National Kyushu Cancer Center, Fukuoka,Japan)

A

No OS benefit with PCI, BM improved<div>1-yr OS 54% vs 48%</div><div>1-yr brain mets 33% vs 59%</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

What is median OS in the CASPIAN trial for the 3 study arms?

A

10.4 months in durvalumab + tremelimumab + plat/etop<div>12.9 months in durvalumab + plat/etop</div><div>10.5 months in plat/etop</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Describe study set-up of the TROVO (IJROBP 2020, NCI of Aviano, Italy) trial in malignant pleural mesothelioma.

A

Phase III study<div>Lung-sparing surgery and platinum + pemetrexed followed by hemithoracic tomotherapy 50 Gy to pleural cavity + 60 Gy SIB to gross disease</div><div>vs</div><div>Lung-sparing surgery and platinum + pemetrexed followed by palliative radiation to surgical scar and/or gross residual<br></br></div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

What was mean OS in the TROVO malignant mesothelioma trial for each study arm?

A

58% vs 28%<div>in favor of the group with hemithoracic RT as compared to palliative radiation to scar and/or gross residual disease</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

What was incidence of procedure tract metastasis in the SMART study?

A

9% vs 16%, p= 0.14<div>There is a trend to benefit of immediate RT to procedure tracts in mesothelioma, but the results were nonsignificant and do not support routine use.</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

In the RTOG 0617, what was the 2-yr and 5-yr OS for 74 Gy vs 60 Gy in patients with unresectable stage III NSCLC

A

2 yr OS was 45% for 74 Gy vs 58% for 60 Gy<div>5 yr OS was 23% for 74 Gy vs 32% for 60 Gy</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

When was chemo and radiation given in the LUNG-ART trial?

A

Chemo was given either neoadjuvant or adjuvant<div>Radiation was either given 2-6 weeks after chemo (chemo adjuvant)</div><div>or</div><div>4-8 weeks after surgery (chemo neo-adjuvant)</div>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

What was the study set-up of the SWOG 9416 / INT 0160

A

2-cycles of cis/etop + 45 Gy –> if no progression then surgery in 3-5 weeks –> followed by cis/etop x2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

What was the conclusion of the meta-analysis performed by the ‘PCI Collaborative Group Gustave-Roussy?

A

Meta-analysis comparing PCI vs no PCI<div><br></br><div>PCI improves OS for SCLC in CR (5% increase at 3-years)</div><div>PCI leads to less brain mets (33% vs 59%)</div></div>

64
Q

What was the conclusion of the PREMER trial?

A

Hippocampal avoidance preserves memory in SCLC PCI.

65
Q

What is the clinical relevance of RTOG 0617?

A

1) In unresectable stage III NSCLC, dose escalation to 74 Gy led to worse outcome.<div>2) In unresectable stage III NSCLC, cetuximab provides no benefit in OS.</div>

66
Q

What are the 5-year OS outcomes in standard of care treatment for Stage IIIA NSCLC in the RTOG 0617, PACIFIC and RTOG 9410

A

RTOG 0617: 66% 2-y OS<div>PACIFIC: 53% 2-y OS</div><div>RTOG 9410: 42% 2-y OS</div>

67
Q

In the combined analysis of STARS and ROSEL, what was 3-y OS and 3-yrs RFS in SABR vs surgery?

A

3-yrs OS 95% SABR vs 79% surgery (significant)<div>3-yr RFS 86% SABR vs 80% surgery (ns)</div><div>However! Even this combined analysis is underpowered!</div>

68
Q

Which studies comparing SABR vs surgery are ongoing?

A

VALOR and STABL-MATES<div>VALOR: VA office of research and development</div><div>STABL-MATES: UTSW</div>

69
Q

What was the SINDAS trial?

A

Evaluated RT in oligometastasis<div>Specifically, in NSCLC, EGFR+, <=5 oligometastasis, non-intracranial</div><div><br></br></div><div>Phase III study</div><div>SBRT to all sites + TKI</div><div>vs</div><div>TKI</div>

70
Q

What did the SABR-COMET study investigate? Describe inclusion criteria

A

RT in oligometastatic disease<div><br></br></div><div>Inclusion criteria:</div><div><= 5 oligometastases</div><div>any histology, controlled primary tumor from definitive treatment</div><div><br></br></div>

71
Q

What was median OS and 5-year OS in the Turrisi trial/INT 0096?

A

Median OS was 23 months for bid vs 19 months for daily fractionation.<div>5-year OS was 26% vs 16%</div>

72
Q

What was the downside of the EORTC 08993/22993?

A

This trial was performed prior to the MRI area.

73
Q

What was the downside of the FIRE-SCLC trial?

A

It was a retrospective study with propensity score analysis which does not replace a randomized trial.

74
Q

What was the regimen studied in the RTOG 9410?

A

Concurrent vs sequential CRT being;<div>seq cis/vinbl then 60 Gy</div><div>vs</div><div>con cis/vinbl + 60 Gy RT</div><div>vs</div><div>conc cis/etoposide RT BID</div>

75
Q

In the INT 0139 / RTOG 9309, what was median OS and 5-yrs OS for neoadj CRT + surgery vs definitive CRT?

A

Median OS was 23 months in both arms<div>5-yrs OS was 27% vs 20%, but NS</div>

76
Q

What was the conclusion of the SWOG 9416 / INT 0160 trial?

A

For superior sulcus tumors, chemoRT followed by surgery then adjuvant chemo is feasible and with favorable response, LC and OS.

77
Q

What was median PFS, median OS and median time to DM or death in the PACIFIC trial comparing adjuvant durvalumab in stage III NSCLC treated with CCRT to placebo?

A

Median PFS: 17.2 vs 5.6 months<div>Median OS: 47.5 vs 29 months</div><div>Median time to death or DM: 28.3 vs 16.2 months</div>

78
Q

What was the conclusion of the EORTC 08993/22993 study?

A

PCI reduces symptomatic brain mets and improves DFS and OS<div>1-yr OS: 27% vs 13%</div><div>1-yr symptom detected BM: 15% vs 40%</div>

79
Q

What was the rate of 3D-CRT in the LUNG-ART trial?

A

89%

80
Q

What did the FIRE SCLC study investigate?

A

A retrospective study of 28 centers which compared SRS to WBRT in SCLC with brain metastasis.

81
Q

In the RTOG 0617, what was the median OS in 74 Gy vs 60 Gy?

A

Median OS: 20 months for 74 Gy vs 29 months for 60 Gy

82
Q

What were the radiation pneumonitis numbers in STRIPE vs WashU?<div><br></br></div><div><br></br></div>

A

<div>STRIPE:</div>

<div>V20<20%: 18% grade 2</div>

<div>V20 20-30%: 30% grade 2</div>

<div>V20 30-40%: 33% grade 2</div>

<div>V20 >40%: 36% grade 2</div>

<div><br></br></div>

<div>WashU</div>

<div>V20<22%: 0%</div>

<div>V20 22-31%: 8%</div>

<div>V20 32-40%:13%</div>

<div>V20>40%: >35%</div>

83
Q

What was the study set-up of the EORTC 08941?

A

Induction platinum-based chemo X3, then if response radical resection +/- PORT<div>vs</div><div>60 Gy definitive RT</div>

84
Q

<div>Which study group did the 'local consolidative treatment' of OliGomez MDACC study?</div>

A

Stage IV NSCLC, 0-3 oligometastases as counted after chemo.

85
Q

What is the cited absolute OS benefit in limited stage SCLC for CCRT vs chemo only.

A

Absolute 5% benefit in OS according to a meta-analysis of the Toronto group<div>Similar results in a meta-analysis of Gustave-Roussy</div>

86
Q

What did the NRG/RTOG 0937 study?

A

Patients with ES-SCLC, consolidative RT to thorax and original sites of mets

87
Q

What were the results (MS) of the EORTC 08941?

A

No difference in MS, 16.4 months vs 17.5 months between surgery vs definitive RT arm

88
Q

What was the conclusion of the EORTC 08941?

A

After response to induction chemo then surgery, surgery doesn’t improve OS of PFS compared to chemoRT alone in stage IIIA N2 NSCLC

89
Q

“What was the most important result of the RTOG 0813 study ‘dose escalation in centrally located tumors””?”

A

3/25 deaths in the 11.5 Gy and 1/21 deaths in the 12 Gy<div>3 of these deaths were bronchopulmonary hemorrhages.</div><div>–> lower doses seem preferred</div>

90
Q

Describe study methods of the CALGB 30610 dose-escalation trial for limited stage SCLC?

A

45 Gy BID<div>vs</div><div>70 Gy</div><div>vs</div><div>61.2 Gy in 1.8 concom boost, qday for 16 fx then BID for 9fx</div><div><br></br></div><div>with cis/etoposide 4 cycles, then PCI if CR or near CR</div>

91
Q

What was 2-yr LF and 2 and 5-yr OS in ENI vs IFRT in the Shandong Cancer Hospital & Institute?

A

2 yr LF: 51% in ENI and 36% in IFRT<div>2-yr OS 26% ENI vs 39% IFRT (p = 0.048)</div><div>5-yr OS 18% vs 25% (NS)</div>

92
Q

What did the INT PCI 99-01/EORTC/RTOG 0212/IFCT study?

A

Dose escalation for PCI in patients with limited-stage SCLC in CR after chemo and RT<div>25 Gy /10fx</div><div>vs</div><div>36 Gy/18 QD or 36 Gy/24 BID</div>

93
Q

What was the maximum tolerated dose in the MSKCC dose-escalation trial?

A

84 Gy

94
Q

What were the findings of the CALGB 8433?

A

Induction chemotherapy improves OS in NSCLC<div>Median OS 9.7 months vs 13.8 months in induction group</div>

95
Q

What was the conclusion of the study investigating adjuvant docetaxel after definitive chemoRT?

A

Consolidation docetaxel after RT with concurrent cisplatin and etoposide results in increased toxicity with no improvement in OS.

96
Q

What was the conclusion of the LUNG-ART study?

A

There was no benefit in DFS or OS with post-op RT for N2 disease with complete resection<div>RT had less mediastinal recurrence and death from progression, but higher deaths from toxicity</div>

97
Q

What was the result of the FIRE-SCLC study?

A

WBRT was associated with improved CNS-TTP over SRS but not OS

98
Q

What are lung constraints in the IMPRINT ph III trial (IMRT in malignant mesothelioma)

A

lung V20 < 37%, mean < 20.5 Gy<div>ipsilateral each lung V40 <67%</div><div>contralateral Lung R V5%<50% - lung L mean <8</div>

99
Q

In the PET-Plan study, what was LRR in IFRT vs ENI?

A

14% in IFRT vs 29% in ENI (0.039)

100
Q

Which study has replace the ANITA trial?

A

The LUNG-ART trial

101
Q

What were the results of the Netherlands Cancer Institute study in terms of overall response rate, median PFS and median OS, in metastatic NSCLC comparing SBRT+pembrolizumab to pembrolizumab?

A

3-month overall response rate was 36% vs 18%, p=0.07<div>median PFS was 6.6 months vs 1.9 months (ns)</div><div>median OS was 15.9 vs 7.6 months (ns)</div><div><br></br></div><div>Overall response rate did not meet the predetermined thresholds but results do favor SBRT</div>

102
Q

Kondo et al. (University of Tokushima, Japan) did a retrospective review of thymic epithelial tumors, what was OS in stage III/IV thymoma and thymic carcinoma STR vs GTR?

A

stage III-IV: 5-yrs OS was 93% for GTR - 64% for STR<div>Thymic carcinoma: 5-yrs OS was 67% for GTR, 30% for STR</div>

103
Q

What was the study population studied in the RTOG 0617?

A

Unresectable stage III NSCLC<div>N = 544</div>

104
Q

What was median OS and 5-yr OS in the SABR COMET study?

A

Median OS 50 vs 28 months<div>5-year OS 42% vs 18% (significant)</div>

105
Q

What is the study design of the SAKK17/04 trial in mesothelioma patients (stage T1-3, N0-2, M0)

A

Phase III ranzomized<div>3 cycles of cis/pemetrexed –> EPP –> if macroscopic resection –></div><div>RT vs no RT</div>

106
Q

Which studies established IFRT vs elective nodal irradiation in NSCLC?

A

PET-PLAN and a study of Shandong Cancer Hospital & Institute

107
Q

How was the phase III clinical trial called which investigated PCI-HA (PCI-hippocampal avoidance)?

A

The ‘PREMER’ trial.

108
Q

How can you interpret the results of the IMpower133 trial?

A

First line atezolizumab in extensive stage SCLC improves OS and PFS, and delays time to intracranial progression

109
Q

What was the patient population studied in the INT 0139 / RTOG 9309?

A

Patients with stage IIIA (pN2) NSCLC, technically resectable<div>N = 396</div>

110
Q

What was the rate of acute esophageal toxicity (grade 3-4) in concurrent vs sequential chemorads?

A

18% vs 4%

111
Q

What were the results of ‘ANITA’s’ subanalysis regarding PORT.

A

pN1: Benefit for PORT if no chemo given<div>2.2 yrs vs 4.2 yrs<br></br><div>pN2: Benefit for PORT with and without chemo</div></div><div>with chemo: 2.0 yrs vs 3.9 yrs</div><div>without chemo: 1.1 yrs vs 1.9 yrs</div>

112
Q

Describe the dose-escalation RTOG 0813 trial for centrally located tumors?

A

SBRT trial in centrally located T1-T2<5cm tumors, medically inoperable<div>Dose escalation 10, 10.5, 11, 11.5, 12Gy SBRT x 5fx</div><div>Endpoint was grade 3+ toxicity</div>

113
Q

What was the conclusion of the PCI dose escalation trial of INT PCI 99-01/EORTC/RTOG 0212/IFCT study.

A

OS was worse in higher dose

114
Q

What was the 2-year OS of the CREST trial evaluating thoracic RT + PCI vs PCI in patients with ES-SCLC with response to chemo?

A

2-yr OS was 13% vs 3% (significant!)<div><br></br></div><div>–> Consolidative thoracic RT improves OS in extensive stage SCLC that responded to chemo</div><div>Benefit only in those with residual disease (which 89% of patients had)</div>

115
Q

What is the ongoing NRG CC009 trial?

A

<div>It is a trial in SCLC with 1-10 brain mets comparing SRS vs 30 Gy hippocampal avoidance IMRT</div>

<div>Primary endpoint is time to cognitive failure</div>

116
Q

What did the SPACE trial investigate and what was it’s study population?

A

SBRT vs EBRT in T1-2N0M0 inoperable patients or patients refusing surgery.

117
Q

What was the conclusion of the RTOG 0236 trial?

A

SBRT for peripheral lung lesions is feasible and results in high LC and LRC.

118
Q

What did the ADAURA trial investigate?

A

Osimertinib in NSCLC EGFR+ s/p complete resection and negative brain imaging.<div><br></br></div><div>Study set-up:</div><div>Osimertinib x3 years</div><div>vs</div><div>Placebo x3 years</div>

119
Q

What were the results (median OS and PFS) of the SINDAS trial, evaluating SBRT for oligometastatic disease in NSCLC EGFR+

A

Median OS was 25.5 vs 17.4 months (p-value significant but 95% CI included 1…)<div>PFS: 20.2 vs 12.5 months</div>

120
Q

What did the EORTC 08993/22993 in ES-SCLC study?

A

4-6 cycles of chemo, wait 4-6 weeks, then if any response to therapy –> PCI (20-30 Gy) vs observation

121
Q

In the RTOG 0617, what was the 5-yr LF, LRF, PFS and DM for 74 Gy vs 60 Gy?

A

In the RTOG 0617, a dose escalation trial in unresectable stage III disease:<div>5-yr LF was 38% vs 46% (trend)</div><div>5-yr LRF was 35.7% vs 38.4% (p= 0.05)</div><div>5-yr PFS was 13% vs 18% (trend)</div><div>5-yr was 52% vs 58% (ns)</div>

122
Q

How did the RTOG 0236 differ from the RTOG 0618?

A

<div>Both trials focused on SBRT for peripheral lesions</div>

<div><br></br></div>

In the RTOG 0236, <u>T1-T2</u> NSCLC, medically <u>inoperable</u>, peripheral lesions were investigated<div>In the RTOG 0618, <u>operable T1-3</u> N0M0 peripheral lesions were investigated</div>

123
Q

What did the PACIFIC trial study?

A

Adjuvant durvalumab vs placebo in patients with stage III, unresectable NSCLC without disease progression after CCRT.

124
Q

Other than the Japanese trial requiring MRI prior to PCI, what was another difference in the EORTC trial vs the Japanese trial which may have influenced study results?

A

The Japanese study screened for brain mets while the EORTC evaluated symptomatic brain mets only.

125
Q

What was the study population studied in the RTOG 9410?

A

Locally advanced NSCLC<div>N = 597</div>

126
Q

What was the conclusion of the SPACE trial?

A

SBRT has less toxicity than 3DCRT. SBRT has a trend towards less progression. There is no change in PFS or OS in SBRT vs 3DCRT

127
Q

Whatwas median LR-RFS in the SAKK17/04 trial and what was the conclusion?

A

Median LR-RFS was 7.6 vs 9.4 months with RT<div>Findings did not support the use of hemithoracic RT after neoadjuvant CHT and EPP</div>

128
Q

What did the RTOG 9410 study?

A

se cis/vinbl then 60 Gy<div>vs</div><div>conc cis/vinbl + 60 Gy RT</div><div>vs</div><div>conc cis/etop + RT BID</div>

129
Q

How did the INT 0139/RTOG 9309 affect treatment of stage IIIA (N2) NSCLC

A

It provided the basis for surgical resection of stage IIIA (N2) with lobectomy

130
Q

What was the difference in population between the INT 0139/RTOG 9309 vs EORTC 08941?

A

In the INT 0139/RTOG 9309, technically resectable stage IIIA (pN2) NSCLC was investigated.<div>In the EORTC 08941, technically unresectable (N2) NSCLC was investigated.</div>

131
Q

Describe RT regimen for both arms in the SPACE trial.

A

SBRT 66 Gy/3fx to isocenter (~ 45 Gy/3 fx to PTV)<div>vs</div><div>70 Gy in 35 fx</div>

132
Q

What was the conclusion of the Kondo retrospective review on thymoma’s regarding RT?

A

No benefit to RT in stage III-IV thymoma or thymic carcinoma, or in GTR stage II-III thymoma

133
Q

What was for us the most important subanalysis of the ANITA trial?

A

The ANITA trial recommended 45-60 Gy for N+<div>They performed a subanalysis of the patients treated with RT</div>

134
Q

What was RT regimen in the INT 0139 / RTOG 9309?

A

Neoadjuvant CRT + surgery: 45 Gy with concurrent cis/etop –> if no PD –> surgery<div>vs</div><div>Definitive RT: 61 Gy total</div><div><br></br></div><div>followed by adjuvant x2 cis/etop in both arms</div>

135
Q

Which group demonstrated a clear benefit of starting RT early (i.e. with cycle 1 or 2) in limited stage SCLC?

A

UNC Chapel Hill, NC

136
Q

What was the difference between the EORTC 08993/22993 PCI trial and the PCI trial performed by the National Kyushu Cancer Center (Fukuoka,Japan).

A

The Japanese trial required no brain metastases on MRI.<div>The EORTC trial was prior to the MRI era.</div>

137
Q

What was the regimen used in the Shandong Cancer Hospital & Institute ENI study?

A

Induction chemo x1 followed by CRT and adjuvant CHT<div>ENI 60-64 Gy</div><div>vs</div><div>IFRT 68-74 Gy</div>

138
Q

What was the study population of, and what did the INT 0139 / RTOG 9309 study?

A

The study population was stage IIIA (pN2) NSCLC, technically resectable<div>Goal of the study was to compare neoadjuvant CRT + surgery</div><div>vs</div><div>definitive RT</div>

139
Q

What was 4-year OS in the patients treated adjuvant with durvalumab in the PACIFIC trial?

A

50% 4-year OS

140
Q

What is the study design in the IMPRINT ph III trial in epithelioid or biphasic malignant pleural mesothelioma stage I-IIIA

A

pleurodectomy/decortication and pemetrexed+platinum<div>followed by</div><div>no RT vs hemithoracic pleural IMRT (45-50.4 Gy)</div>

141
Q

What trial provides the basis for surgical resection of Stage IIIA (N2) with lobectomy?

A

INT 0139/RTOG 9309

142
Q

Describe the study set-up of the PET-PLAN study.

A

RT to PET FDG avid sites and 50 Gy ENI<div>vs</div><div>RT to PET FDG avid sites only</div><div><br></br></div><div>60-74 Gy as high as feasible, concurrent chemo.</div><div>ENI was delivered to stations at >= 10% risk based on an algorithm</div>

143
Q

What were the results of the Peking study cis/etop vs carbo/taxol in terms of 3-yrs OS?

A

3-yrs OS 41% vs 26% for cis/etop vs carbo/taxol

144
Q

What did the lung cancer study group 821 investigate?

A

Lobectomy vs wedge resection with 2 cm margins in T1N0

145
Q

What was 3-yr DFS and OS in the LUNG-ART study for radiation vs no radiation?

A

3-yrs DFS was 47% vs 44% (ns)<div>3-yr OS was 67 vs 69%</div>

146
Q

What are the 2 main studies comparing SABR vs surgery? What were fractionation regimens in both of these studies?

A

STARS and ROSEL<div>STARS: Peripheral 54 Gy /3, central 50 Gy /4</div><div>ROSEL: 54 Gy/3 or 60 Gy in 5</div>

147
Q

What was median OS in seq vs concurrent vs concurrent BID CRT in the RTOG 9410 trial?

A

14.6 months vs 17 months vs 15.6 months<div>(OS SS for arm 2 vs 1, but not for 2 vs 3)<br></br><div>–> Concurrent chemoRT with QD RT results in improved OS</div></div>

148
Q

What was OS and LRF for concurrent vs sequential in the meta-analysis of Goustave-Roussy?

A

5-yr OS increased for concurrent: 15.1% vs 10.6%<div>5-yr LRF improved: 29% vs 35%</div><div><br></br></div><div>–> Concurrent chemorads improves OS compared to sequential CRT</div>

149
Q

What was an important exploratory analysis that was performed in the INT 0139 / RTOG 9309 trial?

A

In exploratory analysis, patients with neoadj CRT followed by lobectomy has improved 5-yrs OS.<div>36% vs 18% 5-yrs OS (the 18% was a matched cohort receiving definitive CRT)</div>

150
Q

What did the MISSILE study investigate?

A

<div>Pathological response after SBRT in T1-2 N0M0.</div>

151
Q

What did the review of Curran (Fox Chase) conclude with regards to RT in stage II-III R0 thymoma patients?

A

In stage II-III, R0: mediastinal recurrence was 53% vs 0% with RT<div>–>R0 alone appears to be inadequate therapy in higher stage thymoma</div>

152
Q

What did the RTOG 0236 study and what was the study population?

A

SBRT in peripheral tumors, NSCLC T1-T2, medically inoperable.

153
Q

Describe methods of NRG/RTOG 0937.

A

Patients with ES-SCLC, 1-4 metastatic lesions and no brain metastases after CR/PR from 4-6 cycles platinum chemo<div><br></br></div><div>PCI 25 Gy only</div><div>vs</div><div>PCI and consolidative RT to thorax and original sites of mets</div><div><br></br></div><div>Recommended dose to chest and mets was 45 Gy in 15 fx but 30-40 Gy was also allowed</div>

154
Q

What were the results of the NRG/RTOG 0937 trial investigating consolidative RT to thorax and mets in ES-SCLC?

A

Consolidative RT to thorax and extracranial metastases delayed progression but did not improve 1-year OS.<div>The trial was closed early due to futility.</div>

155
Q

What was median OS and PFS in the IMpower133 trial (carbo/etop +/- atezolizumab.

A

Median OS was 12.3 months vs 10.3 months<div>Median PFS was5.2 months vs 4.3 months</div><div>in</div><div>atezolizumab + carbo/etop vs placebo + carbo etop</div>

156
Q

What were the conclusions regarding RT in the Japanese retrospective review in Masaoka stage II-III thymoma and thymic carcinoma patients?

A

Stage II-III thymic carcinoma, RT was associated with improves RFS but not OS<div>Stage II-III thymoma, RT was not associated with benefit in RFS or OS</div>

ANKI- Lung (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions